Pimecrolimus Interferes With the Therapeutic Efficacy of Human Mesenchymal Stem Cells in Atopic Dermatitis by Regulating NFAT-COX2 Signaling
August 2021
in “
Stem Cell Research & Therapy
”
Studysummary This study found that coadministration of pimecrolimus may interfere with the therapeutic efficacy of mesenchymal stem cell therapy in atopic dermatitis.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on stemcellres.biomedcentral.com →